Who Can Take PAXLOVID?

The FDA has licensed the emergency use of PAXLOVID for the therapy of mild-to-moderate COVID-19 in adults and youth [12 years of age and older weighing at least 88 kilos (40 kg)] with a wonderful take a look at for the virus that reasons COVID-19, and who are at excessive chance for development to extreme COVID-19, consisting of hospitalization or death, beneath an EUA.

If you take a look at nice for COVID‑19, discuss to your healthcare company as quickly as possible. Your healthcare company can inform you about your cure preferences and if PAXLOVID is terrific for you.

How Effective is Paxlovid

It, also known as nirmatrelvir and ritonavir, is an antiviral medication developed by Pfizer for the treatment of COVID-19. As of my last update in January 2022, Paxlovid had shown promising results in reducing the risk of severe illness and hospitalization in people infected with the SARS-CoV-2 virus. Clinical trials demonstrated its effectiveness in reducing the risk of hospitalization and death by about 89% in high-risk individuals when taken within three days of symptom onset.

However, the effectiveness of treatments can vary based on various factors, including the prevalence of different viral strains and the timing of treatment initiation.

When to take PAXLOVID

It is most effective when taken as early as possible after the onset of COVID-19 symptoms. The medication is intended for adults and certain pediatric patients aged 12 years and older who have tested positive for the virus and are at high risk for progression to severe illness.

It’s crucial to follow your healthcare provider’s instructions regarding the timing and dosage of Paxlovid. Typically, it’s recommended to start treatment within five days of symptom onset. If you test positive for COVID-19 and fall within the high-risk category, contact your healthcare provider promptly to discuss whether it is suitable for you and when to initiate the treatment.


There are no reviews yet.

Be the first to review “BEST PAXLOVID”

Your email address will not be published. Required fields are marked *

error: Content is protected !!